64 results about "LAG3" patented technology

A method for classifying patients at risk for cardiovascular disease, other chronic inflammatory diseases, cardiovascular and / or non-cardiovascular morbidity and mortality based on a risk assessment for lymphocyte activation gene 3 (LAG3) protein deficiency, and for mediating the risk using recombinant lymphocyte activation gene-3 or LAG3 mimetic as a companion therapeutic alone or in combination with a statin and / or an anti-hyperlipidemic drug. The risk assessment is two-prong, beginning with a qualitative determination whether a subject has or is predisposed to abnormal expression of inflammasomes, heightened risk for inflammation and / or to dysfunctional HDL, followed by a quantitative assay or genetic screen for a polymorphism that occurs in the coding sequence of the LAG3 gene. Given positive indication, recombinant LAG3 and / or LAG3 mimetic is used alone or in combination with the therapeutic use of a cholesterol mediating drug for treatment.

The invention relates to LAG-3 binding agents, in particular particularly variable heavy chain (VH) sdAbs and bispecific agents that target both LAG-3 and PD-1, and the use of such binding agents in the treatment, prevention and detection of disease.

The present invention relates to the identification of fibrinogen like protein 1 (FGL1) as a prognostic biomarker for responsiveness to an immune checkpoint inhibitor in a cancer patient. More specifically it relates to methods of treating cancer in a human patient comprising administering an immune checkpoint inhibitory antibody specifically inhibiting the interaction of fibrinogen-like protein 1 (FGL1) with lymphocyte-activation gene 3 protein (LAG3), wherein the cancer is an FGL1 expressing cancer. Further, the invention relates to methods for assessing susceptibility or predicting the responsiveness to the treatment with an immune checkpoint inhibitory antibody specifically inhibiting the interaction of FGL1 with LAG3 in a cancer patient, comprising detecting FGL1 expression in a sample from said patient and to a kit for selecting a cancer patient that would benefit from an immune checkpoint inhibitory antibody specifically inhibiting the interaction of FGL1 with LAG3. The immune checkpoint inhibitory antibody that specifically inhibits the interaction between FGL1 and LAG3 may be an antibody directed against human FGL1 or an antibody directed against human LAG3, optionally in combination with other immune checkpoint inhibitory antibodies, such as an anti-PD1 or an anti-PD-L1 antibody.